文献速递慢性肾脏病肾血管病与高血压

PREVENT方程估算美国CKD人群心血管疾病风险

Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT Equation.
PubMed 文献 · Am J Kidney Dis · 2025-03-05

结果显示PREVENT估算的10年ASCVD风险为8.8%,较PCEs低5.2个百分点;尽管风险估值降低,符合他汀治疗指征者中实际服药者不足半数。

要点

  • PREVENT方程估算CKD人群10年ASCVD风险为8.8%,较PCEs低5.2个百分点
  • PREVENT估算10年心衰风险11.6%,10年CVD风险15.3%
  • 按PREVENT与AHA或KDIGO指南符合他汀一级预防指征者中,接受他汀治疗者不足半数

核心结论

  • 在US CKD人群中,PREVENT方程估算的10年ASCVD风险低于PCEs,但仍存在显著的他汀治疗未满足需求。

主要发现

  • 平均年龄59.8岁(95%CI 59.2-60.4),女性占56.2%(95%CI 52.4%-60.0%)。
  • PREVENT估算10年ASCVD风险为8.8%(95%CI 8.3%-9.4%),较PCEs低5.2个百分点(95%CI 4.6-5.8)。
  • 10年心衰风险为11.6%(95%CI 10.8%-12.3%),10年CVD风险为15.3%(95%CI 14.4%-16.1%)。
  • 按AHA一级预防指南他汀合格比例为63.4%(95%CI 59.8%-67.0%),按KDIGO指南为85.9%(95%CI 83.2%-88.6%)。

关键数值与推荐

  • PREVENT方程纳入eGFR与UACR,PCEs不含肾脏指标。
  • PREVENT估算10年ASCVD风险8.8% vs PCEs低5.2个百分点(95%CI 4.6-5.8)。
  • 基于PREVENT与AHA指南他汀合格率63.4%,与KDIGO指南合格率85.9%。

临床怎么用

  • 对CKD患者可用含eGFR和UACR的PREVENT方程评估10年心血管风险,其ASCVD估值低于PCEs。
  • 符合他汀一级预防指征的CKD患者中实际用药比例偏低,应关注他汀治疗的启动与依从性。

局限性

  • NHANES调查权重并非为该亚组人群推导,且纳入2013年以来数据以保证样本量充足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: The 2023 American Heart Association (AHA) Predicting Risk of Cardiovascular Disease (CVD) EVENTs (PREVENT) equations incorporate estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR). We estimated CVD risk in the US chronic kidney disease (CKD) population using PREVENT and compared the estimates to the 2013 American Heart Association/American College of Cardiology pooled cohort equations (PCEs). STUDY DESIGN: Cross-sectional study. SETTING & PARTICIPANTS: Individuals aged 40-75 years with CKD (eGFR<60mL/min/1.73m2 and/or UACR≥30mg/g) without CVD were identified from National Health and Nutrition Examination Survey (NHANES) data (2013-2020). EXPOSURE: Age, sex, total cholesterol, high-density lipoprotein cholesterol, systolic blood pressure, body mass index, eGFR, diabetes, smoking, antihypertensive use, statin use, urinary albumin-creatinine ratio, hemoglobin A1c. OUTCOME: Estimated 10-year CVD, atherosclerotic CVD (ASCVD), and heart failure risks, and guideline-based statin eligibility. ANALYTICAL APPROACH: Survey methods were used to produce cross-sectional estimates representing the US CKD population. RESULTS: We identified 1,814 eligible individuals, representing 17.5 million people. Their mean age was 59.8 (95% CI, 59.2-60.4) years and 56.2% (95% CI, 52.4%-60.0%) were female. Mean 10-year ASCVD risk in CKD using PREVENT was 8.8% (95% CI, 8.3%-9.4%). This was lower than the risk estimated by PCEs by 5.2 (95% CI, 4.6-5.8) percentage points. The mean estimated 10-year heart failure risk was 11.6% (95% CI, 10.8%-12.3%) and 10-year CVD risk was 15.3% (95% CI, 14.4%-16.1%). The estimated proportion eligible for statin therapy with PREVENT was 63.4% (95% CI, 59.8%-67.0%) using the AHA primary prevention guideline and 85.9% (CI 83.2%-88.6%) using the Kidney Disease Improving Global Outcomes (KDIGO) guideline. Less than half of those eligible for statins for primary prevention based on the PREVENT equation and either the AHA or KDIGO guideline were receiving statin therapy. LIMITATIONS: NHANES survey weights were not derived for this subpopulation, and years dating back to 2013 were included to achieve adequate sample size. CONCLUSIONS: The estimated ASCVD risk was lower with the PREVENT equations compared with the PCEs. Despite the reduced risk estimate, a substantial unmet need for statin therapy in CKD was found. PLAIN-LANGUAGE SUMMARY: Estimating the risk for developing cardiovascular disease (CVD) can guide prevention. Equations to predict cardiovascular risk are available, but the additional risk due to kidney disease has usually been neglected. The 2023 American Heart Association's Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations include kidney measures. We compared the estimated risk of CVD using PREVENT with that using a prior equation (without kidney measures) in people in the United States with chronic kidney disease. We found that the estimated risk of atherosclerotic CVD with the PREVENT equation was lower than with the prior equation, except for in people with the most advanced kidney disease. Despite the reduction in estimated risk, most individuals whose risk qualifies for statins did not report taking them. This highlights a major opportunity to prevent CVD.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Walther CP, Gregg LP, Navaneethan SD, et al. Cardiovascular Disease Risk Estimates in the US CKD Population Using the PREVENT Equation. Am J Kidney Dis. 2025. PMID: 40054593. doi:10.1053/j.ajkd.2025.01.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。